For: | Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 2013; 19(8): 1219-1229 [PMID: 23482703 DOI: 10.3748/wjg.v19.i8.1219] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v19/i8/1219.htm |
Number | Citing Articles |
1 |
Konstantinos C. Fragkos, María Claudia Picasso Bouroncle, Shankar Kumar, Lucy Caselton, Alex Menys, Alan Bainbridge, Stuart A. Taylor, Francisco Torrealdea, Tomoko Kumagai, Simona Di Caro, Farooq Rahman, Jane Macnaughtan, Manil D. Chouhan, Shameer Mehta. Serum Scoring and Quantitative Magnetic Resonance Imaging in Intestinal Failure-Associated Liver Disease: A Feasibility Study. Nutrients 2020; 12(7): 2151 doi: 10.3390/nu12072151
|
2 |
Mirela Loredana Grigoras, Ioana Mihaela Citu, Cosmin Citu, Veronica Daniela Chiriac, Florin Gorun, Mihaela Codrina Levai, Diana Manolescu, Ovidiu Rosca, Felix Bratosin, Srivathsava Gurumurthy, Prima Hapsari Wulandari, Octavian Marius Cretu. Evaluation of FIB-4, NFS, APRI and Liver Function Tests as Predictors for SARS-CoV-2 Infection in the Elderly Population: A Matched Case-Control Analysis. Journal of Clinical Medicine 2022; 11(17): 5149 doi: 10.3390/jcm11175149
|
3 |
Jiwon Yang, Won‐Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Jonggi Choi. Revisiting the steatosis‐associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability. Journal of Gastroenterology and Hepatology 2024; 39(10): 2112 doi: 10.1111/jgh.16656
|
4 |
Jaehyuk Choi, YoungRok Choi, Su young Hong, Sanggyun Suh, Kwangpyo Hong, Eui Soo Han, Jeong-Moo Lee, Suk Kyun Hong, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh. Changes in Indices of Steatosis and Fibrosis in Liver Grafts of Living Donors After Weight Reduction. Frontiers in Surgery 2022; 9 doi: 10.3389/fsurg.2022.827526
|
5 |
Mariana Verdelho Machado, Helena Cortez-Pinto. Non-alcoholic fatty liver disease: What the clinician needs to know. World Journal of Gastroenterology 2014; 20(36): 12956-12980 doi: 10.3748/wjg.v20.i36.12956
|
6 |
Sung Won Chung, Min Kyung Park, Xiao Zhang, Tongtong Wang, Thomas Jemielita, Gail Fernandes, Samuel S. Engel, Heejoon Jang, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim, Xingshun Qi. The Predictive Value of Time‐Varying Noninvasive Scores on Long‐Term Prognosis of NAFLD in South Korea. Canadian Journal of Gastroenterology and Hepatology 2024; 2024(1) doi: 10.1155/2024/5667986
|
7 |
Huihui Liu, Yexuan Cao, Jinglu Jin, Yuanlin Guo, Chenggang Zhu, Naqiong Wu, Qi Hua, Yanfang Li, Lifeng Hong, Qian Dong, Jianjun Li. Liver Fibrosis Scoring Systems as Novel Tools for Predicting Recurrent Cardiovascular Events in Patients with a Prior Cardiovascular Event. Cardiology Discovery 2021; 1(4): 214 doi: 10.1097/CD9.0000000000000033
|
8 |
Steven W. Pipe, K. Rajender Reddy, Pratima Chowdary. Gene therapy: Practical aspects of implementation. Haemophilia 2022; 28(S4): 44 doi: 10.1111/hae.14545
|
9 |
Laura A. Barnes, Yinuo Xu, Ana Sanchez-Azofra, Esteban A. Moya, Michelle P. Zhang, Laura E. Crotty Alexander, Atul Malhotra, Omar Mesarwi. Duration of intermittent hypoxia impacts metabolic outcomes and severity of murine NAFLD. Frontiers in Sleep 2023; 2 doi: 10.3389/frsle.2023.1215944
|
10 |
Julie Poirier, Chloé Cloteau, Audrey Aguesse, Xavier Billot, Etienne Thévenot, Michel Krempf, René Valéro, Marie Maraninchi, Mikaël Croyal. Bariatric Surgery Improves the Atherogenic Profile of Circulating Methylarginines in Obese Patients: Results from a Pilot Study. Metabolites 2021; 11(11): 759 doi: 10.3390/metabo11110759
|
11 |
Shan-Shan Gao, Yue-Liang Shen, Yun-Wen Chen, Xiu-Zhi Wei, Jing-Jing Hu, Jue Wang, Wen-Jing Wu. Liver Metabolomics Analysis Revealing Key Metabolites Associated with
Different Stages of Nonalcoholic Fatty Liver Disease in Hamsters. Combinatorial Chemistry & High Throughput Screening 2024; 27(9): 1303 doi: 10.2174/0113862073238503230924180432
|
12 |
Atilla Engin. Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology 2017; 960: 443 doi: 10.1007/978-3-319-48382-5_19
|
13 |
Antonio De Vincentis, Raffaele Antonelli-Incalzi, Antonio Picardi, Umberto Vespasiani-Gentilucci. Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient. Journal of Diabetes and its Complications 2021; 35(5): 107891 doi: 10.1016/j.jdiacomp.2021.107891
|
14 |
Fabio Nascimbeni, Paola Loria, Vlad Ratziu. Non-Alcoholic Fatty Liver Disease: Diagnosis and Investigation. Digestive Diseases 2014; 32(5): 586 doi: 10.1159/000360510
|
15 |
Katharina Schwarzkopf, Joerg Bojunga, Sabrina Rüschenbaum, Yolanda Martinez, Marcus M. Mücke, Florian Seeger, Fabian Schoelzel, Stefan Zeuzem, Mireen Friedrich‐Rust, Christian M. Lange. Use of Antiplatelet Agents Is Inversely Associated With Liver Fibrosis in Patients With Cardiovascular Disease. Hepatology Communications 2018; 2(12): 1601 doi: 10.1002/hep4.1254
|
16 |
Laura Huiban, Anca Trifan, Carol Stanciu. Essentials of Non-Alcoholic Fatty Liver Disease. 2023; : 229 doi: 10.1007/978-3-031-33548-8_20
|
17 |
Luis Calzadilla‐Bertot, Eduardo Vilar‐Gomez, Vincent Wai‐Sun Wong, Manuel Romero‐Gomez, Rocio Aller‐de la Fuente, Grace Lai‐Hung Wong, Marlen Castellanos, Mohammed Eslam, Archita P. Desai, Gary P. Jeffrey, Jacob George, Naga Chalasani, Leon A. Adams. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver‐Related Cirrhosis. Hepatology 2021; 73(6): 2238 doi: 10.1002/hep.31576
|
18 |
Sun Hwa Lee, Seong Jong Yun, Dong Hyeon Kim, Hyeon Hwan Jo, Yong Sung Park. Severity of nonalcoholic fatty liver disease on sonography and risk of coronary heart disease. Journal of Clinical Ultrasound 2017; 45(7): 391 doi: 10.1002/jcu.22472
|
19 |
Sowbhikh Krishnan M, Sudha R. A STUDY OF NONALCOHOLIC FATTY LIVER DISEASE AND FATTY LIVER INDEX IN TYPE 2 DIABETES MELLITUS PATIENTS. Journal of Evidence Based Medicine and Healthcare 2016; 3(57): 3001 doi: 10.18410/jebmh/2016/654
|
20 |
Ji Eun Lee, Kyung Ok Ko, Jae Woo Lim, Eun Jung Cheon, Young Hwa Song, Jung Min Yoon. Correlation between Transient Elastography (Fibroscan®) and Ultrasonographic and Computed Tomographic Grading in Pediatric Nonalcoholic Steatohepatitis. Pediatric Gastroenterology, Hepatology & Nutrition 2022; 25(3): 240 doi: 10.5223/pghn.2022.25.3.240
|
21 |
Nu'man AS Daud, Nasrul Hadi Akram, Najdah Hidayah, Sri Jayanti, Irda Handayani, Muhammad Nasrum Massi. Gut Microbiome Profiling in Nonalcoholic Fatty Liver Disease and Healthy Individuals in Indonesian Population. Journal of Medical Sciences 2022; 42(4): 166 doi: 10.4103/jmedsci.jmedsci_25_21
|
22 |
Yeo Wool Kang, Yang Hyun Baek, Jong Hoon Lee, Young Hoon Roh, Hee Jin Kwon, Sang Yi Moon, Min Kook Son, Jin Sook Jeong. Assessing the Utility of Acoustic Radiation Force Impulse in the Evaluation of Non-Alcoholic Fatty Liver Disease with Severe Obesity or Steatosis. Diagnostics 2024; 14(11): 1083 doi: 10.3390/diagnostics14111083
|
23 |
Pegah Golabi, Maria Stepanova, Huong T Pham, Rebecca Cable, Nila Rafiq, Haley Bush, Trevor Gogoll, Zobair M Younossi. Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). BMJ Open Gastroenterology 2018; 5(1): e000198 doi: 10.1136/bmjgast-2018-000198
|
24 |
Atilla Engin. Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology 2024; 1460: 539 doi: 10.1007/978-3-031-63657-8_18
|
25 |
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, Anna Alisi, Christopher D. Byrne, Giovanni Targher. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020; 111: 154170 doi: 10.1016/j.metabol.2020.154170
|
26 |
Suzanne E. Mahady, Petra Macaskill, Jonathan C. Craig, Grace L.H. Wong, Winnie C.W. Chu, Henry L.Y. Chan, Jacob George, Vincent W.S. Wong. Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. Clinical Gastroenterology and Hepatology 2017; 15(9): 1453 doi: 10.1016/j.cgh.2017.02.031
|
27 |
Angelina Zhyvotovska, Denis Yusupov, Samy I. McFarlane. Dyslipidemia. 2019; doi: 10.5772/intechopen.85094
|
28 |
Kellyane Santana Dias Carvalho, Carla Hilário da Cunha Daltro, Vinicius Assis Almeida, Raquel Rocha dos Santos, Helma Pinchemel Cotrim. Chronic kidney disease and the severity of non-alcoholic fatty liver disease: a systematic review. Revista da Associação Médica Brasileira 2023; 69(7) doi: 10.1590/1806-9282.20221348
|
29 |
Elif Dincses, Yusuf Yilmaz. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2015; 27(10): 1149 doi: 10.1097/MEG.0000000000000409
|
30 |
George Agyapong, Farzaneh Dashti, Bubu A. Banini. Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies. Annals of the New York Academy of Sciences 2023; 1526(1): 16 doi: 10.1111/nyas.15012
|
31 |
Nuri Baris Hasbal, Sidar Copur, Ibrahim B. Peltek, Ali Mutlu, Hande Ozen Atalay, Yavuz E. Kesgin, Afak Durur Karakaya, Dimitrie Siriopol, Burak Koçak, Mehmet Kanbay. Pancreatic steatosis is an independent risk factor for post‐transplant diabetes mellitus in kidney transplant patients. Clinical Transplantation 2024; 38(1) doi: 10.1111/ctr.15204
|
32 |
Daniel L. Motola, Peter Caravan, Raymond T. Chung, Bryan C. Fuchs. Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. Current Pathobiology Reports 2014; 2(4): 245 doi: 10.1007/s40139-014-0061-z
|
33 |
Changzhou Cai, Xin Song, Yishu Chen, Xueyang Chen, Chaohui Yu. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Hepatology International 2020; 14(1): 115 doi: 10.1007/s12072-019-09964-1
|
34 |
Hiroshi Ishiba, Yoshio Sumida, Seita Kataoka, Masaaki Kuroda, Satoshi Akabame, Kiichiro Tomiyasu, Muhei Tanaka, Masahiro Arai, Hiroyoshi Taketani, Yuya Seko, Akira Okajima, Tasuku Hara, Atsushi Umemura, Taichiro Nishikawa, Kanji Yamaguchi, Michihisa Moriguchi, Hironori Mitsuyoshi, Kohichiroh Yasui, Yoshito Itoh. Association of coronary artery calcification with liver fibrosis in Japanese patients with non‐alcoholic fatty liver disease. Hepatology Research 2016; 46(11): 1107 doi: 10.1111/hepr.12665
|
35 |
Basile Njei, Eri Osta, Nelvis Njei, Yazan A. Al-Ajlouni, Joseph K. Lim. An explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-59183-4
|
36 |
Reeju Amatya, Donghee Lee, Kyoung Ah Min, Meong Cheol Shin. Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy. Pharmaceutics 2023; 15(7): 1963 doi: 10.3390/pharmaceutics15071963
|
37 |
Trace Heavener, Ahmed Memon, Shamyal Khan, Sam Davis, Lauren Sager, Sharon DeMorrow, Mark Jeffries. Testing the ability of the nonalcoholic fatty liver disease fibrosis score to predict 1-year all-cause hospital admission. Baylor University Medical Center Proceedings 2019; 32(1): 26 doi: 10.1080/08998280.2018.1543227
|
38 |
Mehwish Qamar, Abeer Fatima, Ambreen Tauseef, Muhammad I Yousufzai, Ibrahim Liaqat, Qanbar Naqvi. Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease. Cureus 2024; doi: 10.7759/cureus.57943
|
39 |
Giorgio Sesti, Angela Sciacqua, Teresa Vanessa Fiorentino, Maria Perticone, Elena Succurro, Francesco Perticone, Anna Alisi. Association between Noninvasive Fibrosis Markers and Cardio-Vascular Organ Damage among Adults with Hepatic Steatosis. PLoS ONE 2014; 9(8): e104941 doi: 10.1371/journal.pone.0104941
|
40 |
Wayne Eskridge, Donna R. Cryer, Jörn M. Schattenberg, Amalia Gastaldelli, Harmeet Malhi, Alina M. Allen, Mazen Noureddin, Arun J. Sanyal. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective. Journal of Clinical Medicine 2023; 12(19): 6216 doi: 10.3390/jcm12196216
|
41 |
Khara Lucius. Nutritional and Botanical Approaches for Nonalcoholic Fatty Liver Disease. Alternative and Complementary Therapies 2020; 26(6): 246 doi: 10.1089/act.2020.29303.klu
|
42 |
Panyavee Pitisuttithum, Wah-Kheong Chan, George Boon-Bee Goh, Jian-Gao Fan, Myeong Jun Song, Phunchai Charatcharoenwitthaya, Ajay Duseja, Yock-Young Dan, Kento Imajo, Atsushi Nakajima, Khek-Yu Ho, Khean-Lee Goh, Vincent Wai-Sun Wong, Sombat Treeprasertsuk. Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. World Journal of Gastroenterology 2020; 26(19): 2416-2426 doi: 10.3748/wjg.v26.i19.2416
|
43 |
Amila Iriskic Atic, Maja Thiele, Alexander Munk, Louise Torp Dalgaard. Circulating miRNAs associated with nonalcoholic fatty liver disease. American Journal of Physiology-Cell Physiology 2023; 324(2): C588 doi: 10.1152/ajpcell.00253.2022
|
44 |
Vincenzo Solfrizzi, Emanuele Scafato, Carlo Custodero, Francesca Loparco, Alessandro Ciavarella, Francesco Panza, Davide Seripa, Bruno Pietro Imbimbo, Madia Lozupone, Nicola Napoli, Giuseppina Piazzolla, Lucia Galluzzo, Claudia Gandin, Marzia Baldereschi, Antonio Di Carlo, Domenico Inzitari, Alberto Pilotto, Carlo Sabbà. Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2020; 6(1) doi: 10.1002/trc2.12065
|
45 |
Jenny Lee, Yasaman Vali, Jerome Boursier, Rene Spijker, Quentin M. Anstee, Patrick M. Bossuyt, Mohammad H. Zafarmand. Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review. Liver International 2021; 41(2): 261 doi: 10.1111/liv.14669
|
46 |
Longyang Zhu, Yinong Chen, Qing Li, Zhe Wang, Siqi Jiao, Shuwen Zheng, Furong Yang, Yihong Sun. Liver Fibrosis Scores as Predictors of Long-term Outcomes in Patients with ST-segment Elevation Myocardial Infarction. Cardiovascular Innovations and Applications 2024; 9(1) doi: 10.15212/CVIA.2023.0095
|
47 |
Mark CC Cheah, Arthur J McCullough, George Boon-Bee Goh. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. Journal of Clinical and Translational Hepatology 2017; (XX): 1 doi: 10.14218/JCTH.2017.00009
|
48 |
Leon A. Adams, Wah-Kheong Chan. Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future. Seminars in Liver Disease 2020; 40(04): 331 doi: 10.1055/s-0040-1713006
|
49 |
Serkan Dogan, Mehmet Celikbilek, Yunus K. Yilmaz, Savas Sarikaya, Gokmen Zararsiz, Halil I. Serin, Elif Borekci, Lütfi Akyol, Ilyas Pirti, Sena E. Davarci. Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2015; 27(3): 298 doi: 10.1097/MEG.0000000000000286
|
50 |
Per Stål. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World Journal of Gastroenterology 2015; 21(39): 11077-11087 doi: 10.3748/wjg.v21.i39.11077
|
51 |
Vlad Ratziu. Clinical Dilemmas in Non‐Alcoholic Fatty Liver Disease. 2016; : 111 doi: 10.1002/9781118924938.ch13
|
52 |
Hirokazu Takahashi, Keiko Asakawa, Yoshinori Kosakai, Takumi Lee, Mitsuhiro Rokuda. Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis. Diabetes, Obesity and Metabolism 2024; 26(3): 997 doi: 10.1111/dom.15399
|
53 |
Shuo-Yan Gau, Ching-Hua Huang, Yih Yang, Tung-Han Tsai, Kuang-Hua Huang, Chien-Ying Lee. The association between non-alcoholic fatty liver disease and atopic dermatitis: a population-based cohort study. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1171804
|
54 |
Zobair M. Younossi, Linda Henry. Are Noninvasive Scoring Systems for Persons With Chronic Liver Disease Ready for Prime Time?. Gastroenterology 2020; 158(1): 40 doi: 10.1053/j.gastro.2019.11.024
|
55 |
Constanze Bardach, Leonie Morski, Katharina Mascherbauer, Carolina Donà, Matthias Koschutnik, Kseniya Halavina, Christian Nitsche, Dietrich Beitzke, Christian Loewe, Elisabeth Waldmann, Michael Trauner, Julia Mascherbauer, Christian Hengstenberg, Andreas Kammerlander. Comparison of Hepatic Tissue Characterization between T1-Mapping and Non-Contrast Computed Tomography. Journal of Clinical Medicine 2022; 11(10): 2863 doi: 10.3390/jcm11102863
|
56 |
I. A. Bulatova, A. M. Miftakhova, I. L. Gulyaeva. Method for diagnosing non-alcoholic liver steatosis. Medical alphabet 2021; 1(30): 53 doi: 10.33667/2078-5631-2021-30-53-56
|
57 |
Srinevas K. Reddy, David A. Geller. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set. 2017; : 1065 doi: 10.1016/B978-0-323-34062-5.00071-6
|
58 |
M. Del Ben, L. Polimeni, F. Baratta, S. Bartimoccia, R. Carnevale, L. Loffredo, P. Pignatelli, F. Violi, F. Angelico. Serum Cytokeratin-18 Is Associated with NOX2-Generated Oxidative Stress in Patients with Nonalcoholic Fatty Liver. International Journal of Hepatology 2014; 2014: 1 doi: 10.1155/2014/784985
|
59 |
Tae Jung Oh, Kyuho Kim, Jae Hoon Moon, Sung Hee Choi, Nam H Cho, Hak Chul Jang. Liver Fibrosis Indices for the Prediction of Mortality in Korean Subjects: A 16-Year Prospective Cohort Study. Journal of the Endocrine Society 2021; 5(10) doi: 10.1210/jendso/bvab123
|
60 |
Shoham DABBAH, Gil BEN YAKOV, Monika-Inda KAUFMANN, Oranit COHEN-EZRA, Maria LIKHTER, Yana DAVIDOV, Ziv BEN ARI. Predictors of advanced liver fibrosis and the performance of fibrosis scores: lean compared to non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) patients. Minerva Gastroenterology 2024; 70(3) doi: 10.23736/S2724-5985.23.03518-0
|
61 |
Jincheng Wang, Tao Qin, Jinyu Sun, Shiwu Li, Lihua Cao, Xiaojie Lu. Non-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease. Frontiers in Physiology 2022; 13 doi: 10.3389/fphys.2022.1046497
|
62 |
Zong Jie Koh, Hrishikesh Pandurang Salgaonkar, Wei Jie Jonathan Lee, Guo Wei Kim, Chun Hai Tan, Anton Cheng, Davide Lomanto, Jimmy Bok Yan So, Yock Young Dan, Asim Shabbir. Improvement in Non-alcoholic Fatty Liver Disease Score Correlates with Weight Loss in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy: a Two-Centre Study from an Asian Cohort. Obesity Surgery 2019; 29(3): 862 doi: 10.1007/s11695-018-3581-5
|
63 |
Shanwen Charleen Yeo, Weijie Marc Ong, Kui Sing Anton Cheng, Chun Hai Tan. Weight Loss After Bariatric Surgery Predicts an Improvement in the Non-alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score. Obesity Surgery 2019; 29(4): 1295 doi: 10.1007/s11695-018-03676-5
|
64 |
Michelle D. Lundholm, Sarah Kirschling, Bo Hu, Ali Aminian, David E. Arterburn, Anita P. Courcoulas, David E. Cummings, William F. Gourash, Mary Elizabeth Patti, Philip R. Schauer, Donald C. Simonson, Ashley H. Vernon, John P. Kirwan, Sangeeta R. Kashyap. Long‐term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction‐associated fatty liver disease in adults with obesity and type 2 diabetes. Diabetes, Obesity and Metabolism 2024; 26(12): 6055 doi: 10.1111/dom.15932
|
65 |
Yun‐hao Xun, Jian‐chun Guo, Guo‐qiang Lou, Yan‐ming Jiang, Zhen‐jie Zhuang, Meng‐fei Zhu, Yan Luo, Xiao‐jie Ma, Jing Liu, Dong‐xue Bian, Jun‐ping Shi. Non‐alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6‐year overall mortality of Chinese patients with NAFLD. Clinical and Experimental Pharmacology and Physiology 2014; 41(9): 643 doi: 10.1111/1440-1681.12260
|
66 |
Laurent Castera, Valérie Vilgrain, Paul Angulo. Noninvasive evaluation of NAFLD. Nature Reviews Gastroenterology & Hepatology 2013; 10(11): 666 doi: 10.1038/nrgastro.2013.175
|
67 |
Hyun-Seok Kim, Laura Rotundo, Neil Kothari, Sung-Hoon Kim, Nikolaos Pyrsopoulos. Vitamin D Is Associated with Severity and Mortality of Non-alcoholic Fatty Liver Disease: A US Population-based Study. Journal of Clinical and Translational Hepatology 2017; (XX): XX doi: 10.14218/JCTH.2017.00025
|
68 |
Long Wang, Mian Li, Zhiyun Zhao, Min Xu, Jieli Lu, Tiange Wang, Yuhong Chen, Shuangyuan Wang, Meng Dai, Yanan Hou, Xueyan Wu, Lina Ma, Lin Li, Shanshan Liu, Weiqing Wang, Yu Xu, Yufang Bi, Guang Ning. Ideal Cardiovascular Health Is Inversely Associated with Nonalcoholic Fatty Liver Disease: A Prospective Analysis. The American Journal of Medicine 2018; 131(12): 1515.e1 doi: 10.1016/j.amjmed.2018.07.011
|
69 |
Jia Peng, Ming-Ming Liu, Jing-Lu Jin, Ye-Xuan Cao, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Qian Dong, Jing Sun, Rui-Xia Xu, Jian-Jun Li. NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study. Lipids in Health and Disease 2022; 21(1) doi: 10.1186/s12944-021-01610-w
|
70 |
Sara Saki, Nader Saki, Hossein Poustchi, Reza Malekzadeh. Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events. Middle East Journal of Digestive Diseases 2020; 12(2): 65 doi: 10.34172/mejdd.2020.166
|
71 |
Eoin Donnellan, Thomas G. Cotter, Oussama M. Wazni, Mohamed B. Elshazly, Arshneel Kochar, Bryan Wilner, Divyang Patel, Mohamed Kanj, Ayman Hussein, Bryan Baranowski, Daniel Cantillon, Brian Griffin, Wael Jaber, Walid I. Saliba. Impact of Nonalcoholic Fatty Liver Disease on Arrhythmia Recurrence Following Atrial Fibrillation Ablation. JACC: Clinical Electrophysiology 2020; 6(10): 1278 doi: 10.1016/j.jacep.2020.05.023
|
72 |
Tanawat Jongraksak, Abhasnee Sobhonslidsuk, Janjira Jatchavala, Daruneewan Warodomwichit, Piyaporn Kaewduang, Somnuek Sungkanuparph. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people. International Journal of STD & AIDS 2021; 32(3): 266 doi: 10.1177/0956462420960997
|
73 |
Mohit Saran, Jugal Kishore Sharma, Aastha Ranjan, Saurav Deka, Mudit Sabharwal, Srivani Palukari, Betina Chandolia. A retrospective study to find out the correlation between NAFLD, diabetes, and obesity in Indian patients. Journal of Family Medicine and Primary Care 2022; 11(7): 3504 doi: 10.4103/jfmpc.jfmpc_2212_21
|
74 |
H. Perazzo, M. Munteanu, Y. Ngo, P. Lebray, N. Seurat, F. Rutka, M. Couteau, S. Jacqueminet, P. Giral, D. Monneret, F. Imbert-Bismut, V. Ratziu, A. Hartemann-Huertier, C. Housset, T. Poynard. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. Alimentary Pharmacology & Therapeutics 2014; 40(9): 1081 doi: 10.1111/apt.12946
|
75 |
Hui‐Hui Liu, Ye‐Xuan Cao, Jing‐Lu Jin, Qi Hua, Yan‐Fang Li, Yuan‐Lin Guo, Cheng‐Gang Zhu, Na‐Qiong Wu, Run‐Lin Gao, Jian‐Jun Li. Liver Fibrosis Scoring Systems as Novel Tools for Predicting Cardiovascular Outcomes in Patients Following Elective Percutaneous Coronary Intervention. Journal of the American Heart Association 2021; 10(3) doi: 10.1161/JAHA.120.018869
|
76 |
Allison J. Kwong, Natalie M. Zahr. Serum biomarkers of liver fibrosis identify globus pallidus vulnerability. NeuroImage: Clinical 2023; 37: 103333 doi: 10.1016/j.nicl.2023.103333
|
77 |
Dunya Tomic, Agus Salim, Jacob George, Dianna J. Magliano, Jonathan E. Shaw. Liver disease mortality and hospitalisations among people with type 2 diabetes mellitus: A population‐based study. Liver International 2024; 44(2): 508 doi: 10.1111/liv.15794
|
78 |
Renling Yao, Li Zhu, Jian Wang, Jiacheng Liu, Ruifei Xue, Leyang Xue, Longgen Liu, Chunyang Li, Haiyan Zhao, Juan Cheng, Songping Huang, Yang Li, Xiang‐an Zhao, Chuanwu Zhu, Ming Li, Rui Huang, Chao Wu. Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores. Journal of Clinical Laboratory Analysis 2021; 35(8) doi: 10.1002/jcla.23880
|
79 |
Natalie Zahr, Allison J. Kwong. Serum Biomarkers of Liver Fibrosis Identify Globus Pallidus Vulnerability. SSRN Electronic Journal 2022; doi: 10.2139/ssrn.4194649
|
80 |
Raphaël Decoin, Laura Butruille, Thomas Defrancq, Jordan Robert, Nicolas Destrait, Augustin Coisne, Samy Aghezzaf, Eloise Woitrain, Zouriatou Gouda, Sofia Schino, Cédric Klein, Patrice Maboudou, François Brigadeau, Didier Klug, Andre Vincentelli, David Dombrowicz, Bart Staels, David Montaigne, Sandro Ninni. High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.957245
|
81 |
Giorgio Sesti, Teresa Vanessa Fiorentino, Franco Arturi, Maria Perticone, Angela Sciacqua, Francesco Perticone, Claudia Miele. Association between Noninvasive Fibrosis Markers and Chronic Kidney Disease among Adults with Nonalcoholic Fatty Liver Disease. PLoS ONE 2014; 9(2): e88569 doi: 10.1371/journal.pone.0088569
|
82 |
Karen L. Thomsen, Lionel Hebbard, Emilie Glavind, Andrew Clouston, Hendrik Vilstrup, Jacob George, Henning Grønbæk. Non‐alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. Liver International 2014; 34(10): 1584 doi: 10.1111/liv.12547
|
83 |
Bo Kyung Koo, Donghee Kim, Sae Kyung Joo, Jung Ho Kim, Mee Soo Chang, Byeong Gwan Kim, Kook Lae Lee, Won Kim. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. Journal of Hepatology 2017; 66(1): 123 doi: 10.1016/j.jhep.2016.08.019
|
84 |
Sheila M. Grecian, Stela McLachlan, Jonathan A. Fallowfield, Patrick K. A. Kearns, Peter C. Hayes, Neil I. Guha, Joanne R. Morling, Stephen Glancy, Rachel M. Williamson, Rebecca M. Reynolds, Brian M. Frier, Nicola N. Zammitt, Jackie F. Price, Mark W. J. Strachan. Non‐invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study. Liver International 2020; 40(9): 2252 doi: 10.1111/liv.14590
|
85 |
Marcello Dallio, Moris Sangineto, Mario Romeo, Marina Cipullo, Annachiara Coppola, Simone Mammone, Giuseppe Di Gioia, Mario Masarone, Marcello Persico, Gaetano Serviddio, Alessandro Federico. The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition. Nutrition & Diabetes 2024; 14(1) doi: 10.1038/s41387-024-00294-2
|
86 |
Jiyeon Si, Giljae Lee, Hyun Ju You, Sae Kyung Joo, Dong Hyeon Lee, Bon Jeong Ku, Seoyeon Park, Won Kim, GwangPyo Ko. Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease. Computational and Structural Biotechnology Journal 2021; 19: 5920 doi: 10.1016/j.csbj.2021.10.032
|
87 |
Fabio Nascimbeni, Stefano Ballestri, Mariana Verdelho Machado, Alessandro Mantovani, Helena Cortez-Pinto, Giovanni Targher, Amedeo Lonardo. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Review of Gastroenterology & Hepatology 2018; 12(4): 351 doi: 10.1080/17474124.2018.1415756
|
88 |
Marc–Emmanuel Dumas, James Kinross, Jeremy K. Nicholson. Metabolic Phenotyping and Systems Biology Approaches to Understanding Metabolic Syndrome and Fatty Liver Disease. Gastroenterology 2014; 146(1): 46 doi: 10.1053/j.gastro.2013.11.001
|
89 |
S. Rooban, K. A. Arul Senghor, V. M. Vinodhni, Renuka. P. Elevated serum preptin levels as a marker for non-alcoholic fatty liver disease severity in type 2 diabetes mellitus patients. International Journal of Diabetes in Developing Countries 2024; doi: 10.1007/s13410-024-01419-0
|
90 |
Heejun Son, Bo Kyung Koo, Sae Kyung Joo, Dong Hyeon Lee, Heejoon Jang, Jeong Hwan Park, Mee Soo Chang, Won Kim. PNPLA3 genotypes modify the adverse effect of the total energy intake on high-risk nonalcoholic steatohepatitis development. The American Journal of Clinical Nutrition 2023; 117(5): 910 doi: 10.1016/j.ajcnut.2023.02.024
|
91 |
K.H. Williams, A.J. Viera de Ribeiro, E. Prakoso, A.S. Veillard, N.A. Shackel, Y. Bu, B. Brooks, E. Cavanagh, J. Raleigh, S.V. McLennan, G.W. McCaughan, W.W. Bachovchin, F.M. Keane, A. Zekry, S.M. Twigg, M.D. Gorrell. Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. Diabetes Research and Clinical Practice 2015; 108(3): 466 doi: 10.1016/j.diabres.2015.02.024
|
92 |
Andrew D. Schreiner, Naveed Sattar. Identifying Patients with Nonalcoholic Fatty Liver Disease in Primary Care: How and for What Benefit?. Journal of Clinical Medicine 2023; 12(12): 4001 doi: 10.3390/jcm12124001
|
93 |
Panyavee Pitisuttithum, Wah-Kheong Chan, George Boon-Bee Goh, Jian-Gao Fan, Myeong Jun Song, Phunchai Charatcharoenwitthaya, Ajay Duseja, Yock-Young Dan, Kento Imajo, Atsushi Nakajima, Khek-Yu Ho, Khean-Lee Goh, Vincent Wai-Sun Wong, Sombat Treeprasertsuk. Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. World Journal of Gastroenterology 2020; 26(19): 2415 doi: 10.3748/wjg.v26.i19.2415
|
94 |
Bouharati Khaoula, Bouharati Imene, Guenifi Wahiba, Gasmi Abdelkader, Laouamri Slimane. Artificial Neural Networks Analysis of the Risk Factors for Aneurysm in the Population of the Setif Region in Algeria. WSEAS TRANSACTIONS ON BIOLOGY AND BIOMEDICINE 2022; 19: 163 doi: 10.37394/23208.2022.19.18
|
95 |
Marilena DURAZZO, Letizia MARZARI, Silvia BONETTO, Arianna FERRO, Maria C. GHIGO, Paola BELCI, Alessandro COLLO, Sharmila FAGOONEE. Noninvasive diagnosis of fibrosis in non-alcoholic fatty liver disease: diagnostic accuracy of different scores. Minerva Gastroenterologica e Dietologica 2021; 66(4) doi: 10.23736/S1121-421X.20.02753-1
|
96 |
Hilmar K Lückhoff, Frederik C Kruger, Maritha J Kotze. Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World Journal of Hepatology 2015; 7(9): 1192-1208 doi: 10.4254/wjh.v7.i9.1192
|
97 |
Lissa Franco, Michelle Jones-Pauley, Omar Tamimi, Leila Neshatian, Duc Nguyen, Edward Graviss, Eamonn MM Quigley, David Victor. Irritable Bowel Syndrome Symptoms in Nonalcoholic Fatty Liver Disease Patients Are an Indicator of Depression and Anxiety. Journal of Clinical Gastroenterology 2023; 57(10): 1016 doi: 10.1097/MCG.0000000000001770
|
98 |
Thomai Mouskeftara, Georgios Kalopitas, Theodoros Liapikos, Konstantinos Arvanitakis, Georgios Germanidis, Helen Gika. Predicting Non-Alcoholic Steatohepatitis: A Lipidomics-Driven Machine Learning Approach. International Journal of Molecular Sciences 2024; 25(11): 5965 doi: 10.3390/ijms25115965
|
99 |
Roberta Forlano, Benjamin H. Mullish, Rooshi Nathwani , Ameet Dhar, Mark R. Thursz, Pinelopi Manousou . Non-Alcoholic Fatty Liver Disease and Vascular Disease. Current Vascular Pharmacology 2020; 19(3): 269 doi: 10.2174/1570161118666200318103001
|
100 |
Wei-Jen Ting, Wei-Wen Kuo, Dennis Hsieh, Yu-Lan Yeh, Cecilia-Hsuan Day, Ya-Hui Chen, Ray-Jade Chen, Viswanadha Padma, Yi-Hsing Chen, Chih-Yang Huang. Heat Killed Lactobacillus reuteri GMNL-263 Reduces Fibrosis Effects on the Liver and Heart in High Fat Diet-Hamsters via TGF-β Suppression. International Journal of Molecular Sciences 2015; 16(10): 25881 doi: 10.3390/ijms161025881
|
101 |
Sabine Kahl, Anne Pernille Ofstad, Bernard Zinman, Christoph Wanner, Elke Schüler, Naveed Sattar, Silvio E. Inzucchi, Michael Roden. Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes, Obesity and Metabolism 2022; 24(6): 1061 doi: 10.1111/dom.14670
|
102 |
Zaki A. Sherif, Armana Saeed, Shima Ghavimi, Seyed-Mehdi Nouraie, Adeyinka O. Laiyemo, Hassan Brim, Hassan Ashktorab. Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Digestive Diseases and Sciences 2016; 61(5): 1214 doi: 10.1007/s10620-016-4143-0
|
103 |
Elena Garicano Vilar, Sara Sanz Rojo, Sara López Oliva, Silvia Martínez, Ana Terrén Lora, Ismael San Mauro Martin. Effect of MetioNac® in patients with metabolic syndrome who are at risk of metabolic dysfunction associated fatty liver disease: a randomized controlled trial. Nutrición Hospitalaria 2023; doi: 10.20960/nh.04635
|
104 |
Dilara Hatipoğlu, Connor Mulligan, Jeffrey Wang, Juan Peticco, Reid Grinspoon, Sanjay Gadi, Camilla Mills, Jay Luther, Raymond T. Chung. Differential Effects of COVID-19 Hospitalization on the Trajectory of Liver Disease Progression. Gastro Hep Advances 2023; 2(4): 480 doi: 10.1016/j.gastha.2023.01.020
|
105 |
Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Young Jang, Soo Young Park, Hyun Woong Lee, Chun Kyon Lee, Seung Up Kim. Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.869190
|
106 |
Jun L. Chin, Michael Pavlides, Ahmad Moolla, John D. Ryan. Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?. Frontiers in Pharmacology 2016; 7 doi: 10.3389/fphar.2016.00159
|
107 |
Tetsuya Takahashi, Tetsu Watanabe, Tetsuro Shishido, Ken Watanabe, Takayuki Sugai, Taku Toshima, Daisuke Kinoshita, Miyuki Yokoyama, Harutoshi Tamura, Satoshi Nishiyama, Takanori Arimoto, Hiroki Takahashi, Tamon Yamanaka, Takuya Miyamoto, Isao Kubota. The impact of non-alcoholic fatty liver disease fibrosis score on cardiac prognosis in patients with chronic heart failure. Heart and Vessels 2018; 33(7): 733 doi: 10.1007/s00380-017-1113-1
|
108 |
Federico Salomone, Agnieszka Micek, Justyna Godos. Simple Scores of Fibrosis and Mortality in Patients with NAFLD: A Systematic Review with Meta-Analysis. Journal of Clinical Medicine 2018; 7(8): 219 doi: 10.3390/jcm7080219
|
109 |
Antonio De Vincentis, Luisa Costanzo, Umberto Vespasiani-Gentilucci, Antonio Picardi, Stefania Bandinelli, Luigi Ferrucci, Raffaele Antonelli Incalzi, Claudio Pedone. Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people. Digestive and Liver Disease 2019; 51(9): 1330 doi: 10.1016/j.dld.2019.01.017
|
110 |
Venkateswararao Eeda, Nikhil Yuvaraj Patil, Aditya Dilip Joshi, Vibhudutta Awasthi. Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions. Hepatology Research 2024; 54(3): 222 doi: 10.1111/hepr.14008
|
111 |
Sixu Li, Feng Xiong, Songbo Zhang, Jinghua Liu, Guangping Gao, Jun Xie, Yi Wang. Oligonucleotide therapies for nonalcoholic steatohepatitis. Molecular Therapy - Nucleic Acids 2024; 35(2): 102184 doi: 10.1016/j.omtn.2024.102184
|
112 |
Marta Iruarrizaga-Lejarreta, Fernando Bril, Mazen Noureddin, Pablo Ortiz, Shelly C. Lu, José M. Mato, Cristina Alonso. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. 2019; : 423 doi: 10.1007/978-3-030-11748-1_16
|
113 |
Abdullah Sonsuz, Oguz Kagan Bakkaloglu. Biomarkers in Medicine. 2022; : 490 doi: 10.2174/9789815040463122010020
|
114 |
Adriana Roca-Fernandez, Rajarshi Banerjee, Helena Thomaides-Brears, Alison Telford, Arun Sanyal, Stefan Neubauer, Thomas E. Nichols, Betty Raman, Celeste McCracken, Steffen E. Petersen, Ntobeko AB. Ntusi, Daniel J. Cuthbertson, Michele Lai, Andrea Dennis, Amitava Banerjee. Liver disease is a significant risk factor for cardiovascular outcomes – A UK Biobank study. Journal of Hepatology 2023; 79(5): 1085 doi: 10.1016/j.jhep.2023.05.046
|
115 |
Pichamol Jirapinyo, Thomas R. McCarty, Russell D. Dolan, Raj Shah, Christopher C. Thompson. Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2022; 20(3): 511 doi: 10.1016/j.cgh.2021.03.017
|
116 |
Diego García-Compeán, Jesús Zacarías Villarreal-Pérez, Manuel Enrique de la O. Cavazos, Fernando Javier Lavalle-Gonzalez, Omar David Borjas-Almaguer, Angel Noé Del Cueto-Aguilera, José Alberto González-González, Consuelo Treviño-Garza, Lourdes Huerta-Pérez, Héctor Jesús Maldonado-Garza. Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening?. Annals of Hepatology 2020; 19(3): 258 doi: 10.1016/j.aohep.2020.01.003
|
117 |
Bandita Panda, Suvankar Dey, Ambika P Mohanty. Multivariate Analysis of Predictive Scores for Severity Prediction in Nonalcoholic Fatty Liver Disease Among Obese and Nonobese Patients. The Journal of Medical Sciences 2024; 10(1--4): 1 doi: 10.5005/jp-journals-10045-00292
|
118 |
Lisa C. Adams, Falk Lübbe, Keno Bressem, Moritz Wagner, Bernd Hamm, Marcus R. Makowski, Pavel Strnad. Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study. PLOS ONE 2018; 13(11): e0206450 doi: 10.1371/journal.pone.0206450
|
119 |
Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Per Stål, Rolf Hultcrantz, Stergios Kechagias. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2019; 17(6): 1148 doi: 10.1016/j.cgh.2018.11.030
|
120 |
Meng-Hsuan Hsieh, Kuan-Ta Wu, Yi-Yu Chen, Jeng-Fu Yang, Wen-Yi Lin, Ning-Chia Chang, Chia-Yi Lin, Chao-Kuan Huang, Chao-Ling Wang, Hung-Yi Chuang, Shu-Ching Lin, Yu-Kuei Hsu, Yi-Shan Tsai, Wan-Long Chuang, Ming-Lung Yu, Chia-Yen Dai. Higher NAFLD fibrosis score is associated with impaired eGFR. Journal of the Formosan Medical Association 2020; 119(1): 496 doi: 10.1016/j.jfma.2019.07.007
|
121 |
Sheila M. Grecian, Stela McLachlan, Jonathan A. Fallowfield, Peter C. Hayes, Indra Neil Guha, Joanne R. Morling, Stephen Glancy, Rachel M. Williamson, Rebecca M. Reynolds, Brian M. Frier, Nicola N. Zammitt, Jackie F. Price, Mark W. J. Strachan. Addition of hyaluronic acid to the FIB‐4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Obesity Science & Practice 2021; 7(5): 497 doi: 10.1002/osp4.484
|
122 |
Aynur Unalp‐Arida, Constance E. Ruhl. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology 2017; 66(1): 84 doi: 10.1002/hep.29113
|
123 |
Muharrem Bayrak. Non-invasive diagnosis of nonalcoholic fatty liver disease: impact of age and other risk factors. The Aging Male 2020; 23(5): 1275 doi: 10.1080/13685538.2020.1763293
|
124 |
Cory M. Fielding, Paul Angulo. Hepatic Steatosis and Steatohepatitis: Are they Really Two Distinct Entities?. Current Hepatology Reports 2014; 13(2): 151 doi: 10.1007/s11901-014-0227-5
|
125 |
John B. Dixon. Surgical Management of Obesity in Patients with Morbid Obesity and Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2014; 18(1): 129 doi: 10.1016/j.cld.2013.09.011
|
126 |
Alessandra Gentili, Giulia Daviddi, Stefano De Vuono, Maria Anastasia Ricci, Francesco Di Filippo, Abdalkader Alaeddin, Massimo R. Mannarino, Marcello Boni, Gaetano Vaudo, Graziana Lupattelli. Non-alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients. Digestive and Liver Disease 2016; 48(8): 904 doi: 10.1016/j.dld.2016.04.004
|
127 |
Laurens A. van Kleef, Robert J. de Knegt, Ibrahim Ayada, Qiuwei Pan, Willem Pieter Brouwer. The Steatosis-associated fibrosis estimator (SAFE) score: validation in the general US population. Hepatology Communications 2023; 7(4) doi: 10.1097/HC9.0000000000000075
|
128 |
Veeravich Jaruvongvanich, Karn Wijarnpreecha, Patompong Ungprasert. The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of cohort study. Clinics and Research in Hepatology and Gastroenterology 2017; 41(6): 629 doi: 10.1016/j.clinre.2017.03.010
|
129 |
Guilherme M. Campos, David A. Lanning. Bariatric surgery for nonalcoholic fatty liver disease in adolescents with severe obesity. Surgery for Obesity and Related Diseases 2015; 11(2): 449 doi: 10.1016/j.soard.2014.12.015
|
130 |
G. E. Rojtberg, O. O. Sharkhun. Non-alcoholic fatty liver disease and the myocardial remodeling: the role of insulin resistance in the hepatocardial association development. Experimental and Clinical Gastroenterology 2020; 174(5): 47 doi: 10.31146/1682-8658-ecg-177-5-47-52
|
131 |
Evgin Goceri, Zarine K. Shah, Rick Layman, Xia Jiang, Metin N. Gurcan. Quantification of liver fat: A comprehensive review. Computers in Biology and Medicine 2016; 71: 174 doi: 10.1016/j.compbiomed.2016.02.013
|
132 |
Stanislav Kotlyarov. Immune and metabolic cross-links in the pathogenesis of comorbid non-alcoholic fatty liver disease. World Journal of Gastroenterology 2023; 29(4): 597-615 doi: 10.3748/wjg.v29.i4.597
|